Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02141854
Recruitment Status : Completed
First Posted : May 20, 2014
Results First Posted : April 12, 2017
Last Update Posted : May 31, 2017
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )

Tracking Information
First Submitted Date  ICMJE May 9, 2014
First Posted Date  ICMJE May 20, 2014
Results First Submitted Date  ICMJE February 28, 2017
Results First Posted Date  ICMJE April 12, 2017
Last Update Posted Date May 31, 2017
Study Start Date  ICMJE June 2014
Actual Primary Completion Date September 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 2, 2017)
  • Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12 [ Time Frame: Day 1 (predose, baseline), Week 12 and was performed at the following times relative to the administration of study drug (±5 minutes): 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, and 12 hours ]
    A subset of patients performed postdose serial spirometry. Data from these assessments were used to analyze the primary endpoint of baseline-adjusted FEV1 AUEC0-12h at week 12 using the trapezoidal rule based on actual time of measurement. It was standardized by dividing it by the number of hours between the start time of dose administration and the end time of the last nonmissing FEV1 measurement. The baseline FEV1 was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose). If 1 of these was missing, the nonmissing value was used; if both were missing, baseline was treated as missing. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting the baseline FEV1 value.
  • Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 [ Time Frame: Day 1 (predose, baseline), Week 12 ]
    Trough FEV1 is a morning spirometry taken predose and pre-rescue bronchodilator. The baseline for predose FEV1 was defined as the average of the 30-minute and 10-minute predose measurements obtained at the randomization visit (Day 1).
Original Primary Outcome Measures  ICMJE
 (submitted: May 14, 2014)
  • Change from baseline in trough FEV1 over the 12 week treatment period [ Time Frame: 12 weeks ]
    Change in trough FEV1
  • Baseline-adjusted area under the curve for FEV1 AUC0-12 at week 12 [ Time Frame: 12 weeks ]
    Change in post-dose FEV1 (subset of patients who perform postdose serial spirometry)
Change History Complete list of historical versions of study NCT02141854 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 28, 2017)
  • Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment [ Time Frame: Days -6 to Day 1 (predose, baseline), Day 1 (postdose) daily until Week 12 ]
    Morning PEF tests were performed before administration of study drug or rescue medications (data were excluded if the time of PEF measurement was more than 5 minutes after the dose time). The patient recorded the highest value of 3 measurements obtained in the patient diary. The baseline PEF was the average value of recorded (nonmissing) morning assessments over the 7 days prior to randomization on Day 1. For efficacy analyses of weekly average morning PEF measurements, values were the averages based on available data for that week.
  • Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period [ Time Frame: Days -6 to Day 1 (predose, baseline), to Week 12 ]
    The total daily asthma symptom score is the average of the daytime and nighttime scores as recorded in the patient diary. Daytime Symptom Score:
    • 0=No symptoms
    • 1=Symptoms for 1 short period
    • 2=Symptoms for 2+ short periods
    • 3=Symptoms for most of the day - did not affect normal daily activities
    • 4=Symptoms for most of the day - did affect normal daily activities
    • 5=Symptoms so severe that I could not go to work or perform normal daily activities
    Nighttime Symptom Score (determined in the AM):
    • 0=No symptoms
    • 1=Symptoms causing me to wake once (or wake early)
    • 2=Symptoms causing me to wake twice or more (including waking early)
    • 3=Symptoms causing me to be awake for most of the night
    • 4=Symptoms so severe that I did not sleep Baseline was the average of recorded scores over the 7 days before randomization. The change from baseline in the weekly average over weeks 1 to 12 was analyzed using an mixed model for repeated measures (MMRM).
  • Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period [ Time Frame: Days -6 to Day 1 (predose, baseline), up to week 12 ]
    Patients recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each AM and PM in the diary. The average number of daily inhalations over the 7 days before the randomization visit was the baseline value. The weekly average was based on the available data for the 7 days before each analysis week. The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) over weeks 1 to 12 was analyzed using a mixed model for repeated measures.
  • Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12 [ Time Frame: up to Week 12 of the Treatment Period ]
    The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma, defined as the number of days elapsed from the date of randomization to the date of withdrawal due to worsening asthma. Patients who were lost to follow-up, who had not withdrawn due to worsening asthma by week 12, or who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.
  • Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old [ Time Frame: Day 1 (predose, baseline), end of trial (up to week 12) ]
    The AQLQ(S) (September 2010 version; patients aged ≥18 years) was self administered by the patients at the investigational center at the randomization visit and at Week 12 or end of trial. The questionnaire is a tool to measure the impact of asthma on a patient's quality of life (physical, emotional, social, and occupational) with a recall period of 2 weeks. The AQLQ(S) was administered only to patients 18 years and older. The 32 individual questions in the AQLQ were equally weighted. The overall AQLQ score was the mean of the responses to each of the 32 questions, and ranged from 1 to 7. A score 7.0 indicated that the patient had no impairments due to asthma and a score of 1.0 indicated severe impairment. Positive change from baseline scores indicate improved quality of life.
  • Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1 [ Time Frame: Day 1 of the Treatment Period (predose and postdose) ]
    The baseline forced expiratory volume in 1 second (FEV1) was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose) on Day 1. If one of these was missing, the other measurement was used as baseline value. If both were missing, the baseline trough FEV1 was treated as missing. Time to target improvement (15% or 12%) was defined as the time elapsed from the time of first dose to the first time the target improvement in FEV1 was achieved. If an exact target increase was not achieved at a measured timepoint, then the time was estimated by linear interpolation between the timepoint when target was reached and the timepoint immediately before. Patients who did not achieve the target improvement were censored at the time of last serial spirometry assessment. Values of NA indicate the values could not be estimated which happened when the estimated probability of not achieving target is more than 50%.
  • Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period [ Time Frame: Day 1 to Week 12 of the Treatment Period ]
    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 14, 2014)
  • Change from baseline in the weekly average of the daily trough morning PEF over the 12 week treatment period [ Time Frame: 12 weeks ]
    Change in morning PEF
  • Change from baseline in the Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ(S) at final visit [ Time Frame: 12 weeks ]
    Change in questionnaire score (patients ≥18 years of age only)
  • Change from baseline in Pediatric Asthma Quality of Life Questionnaire with Standardized Activities (PAQLQ(S) at final visit [ Time Frame: 12 weeks ]
    Change in questionnaire score (patients 12 to 17 years of age only)
  • Time to meeting alert criteria for worsening asthma [ Time Frame: 12 weeks ]
    Time to predefined alert criteria for worsening asthma
  • Time to patient withdrawal due to worsening asthma [ Time Frame: 12 weeks ]
    Time to patient withdrawal for worsening asthma
  • Change from baseline in weekly average of asthma symptoms over weeks 1 to 12 [ Time Frame: 12 weeks ]
    Change in average asthma symptom score
  • Change from baseline in weekly average use of albuterol/salbutamol inhalation aerosol over weeks 1 to 12 [ Time Frame: 12 weeks ]
    Change in weekly average (number of albuterol inhalations
  • Time to 15% and 12% improvement from baseline in post-dose FEV1 at TV1 [ Time Frame: 12 hours ]
    Time to 15% and 12% improvement in serial spirometry (subset of patients who perform postdose serial spirometry)
  • Number of participants with adverse events [ Time Frame: From signing of informed consent form to completion of 12 weeks ]
    Incidence and type of adverse events
  • Change from baseline in the weekly average of the daily trough evening PEF over the 12 week treatment period [ Time Frame: 12 weeks ]
    Change in evening PEF
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
Official Title  ICMJE A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy
Brief Summary The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in patients 12 years of age and older with persistent asthma.
Detailed Description Study drug and placebo were supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants performed spirometry at every visit. Each participant was given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) was dispensed at each visit, if needed, as determined by the investigational center personnel.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Asthma
Intervention  ICMJE
  • Drug: FS MDPI

    FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.

    During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.

    Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.

    Other Names:
    • fluticasone propionate
    • inhaled corticosteroid
    • salmeterol xinafoate
    • β2 adrenoceptor agonist
  • Drug: Fp MDPI

    Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.

    During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.

    Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.

    Other Names:
    • fluticasone propionate
    • inhaled corticosteroid
  • Drug: Placebo MDPI
    The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
    Other Name: inert powder
  • Drug: Albuterol/salmeterol HFA MDI
    Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
    Other Name: short-acting β2-adrenergic agonists
Study Arms  ICMJE
  • Experimental: FS MDPI 200 / 12.5 mcg
    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
    Interventions:
    • Drug: FS MDPI
    • Drug: Albuterol/salmeterol HFA MDI
  • Experimental: FS MDPI 100 / 12.5 mcg
    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
    Interventions:
    • Drug: FS MDPI
    • Drug: Albuterol/salmeterol HFA MDI
  • Experimental: Fp MDPI 200 mcg
    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.
    Interventions:
    • Drug: Fp MDPI
    • Drug: Albuterol/salmeterol HFA MDI
  • Experimental: Fp MDPI 100 mcg
    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.
    Interventions:
    • Drug: Fp MDPI
    • Drug: Albuterol/salmeterol HFA MDI
  • Placebo Comparator: Placebo MDPI
    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.
    Interventions:
    • Drug: Placebo MDPI
    • Drug: Albuterol/salmeterol HFA MDI
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 28, 2017)
882
Original Estimated Enrollment  ICMJE
 (submitted: May 14, 2014)
625
Actual Study Completion Date  ICMJE September 2015
Actual Primary Completion Date September 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Best pre-bronchodilator forced expiratory volume in 1 second (FEV1) of 40 to 85% of their predicted normal value.
  2. Current Asthma Therapy: Patients must have a short-acting β2-agonist (for rescue use) for a minimum of 8 weeks before the Screening Visit (SV) and a qualifying dose of an inhaled corticosteroid (ICS). The ICS may be either as ICS monotherapy or as an ICS/long-acting beta agonist (LABA) combination. The ICS component of the patient's asthma therapy should be stable for a minimum of 1 month before providing consent.
  3. Reversibility of Disease: Patients must have at least 15% reversibility (all patients) and at least a 200 mL increase from baseline FEV1 (patients age 18 and older) within 30 minutes after 2 to 4 inhalations of albuterol/salbutamol at the SV. Note: Patients who do not qualify for the study due to failure to meet reversibility will be permitted to perform a retest once within 7 days.
  4. Patients must provide written informed consent/assent.. For minor patients (ages 12 to 17 years, or as applicable per local regulations), the written ICF must be signed and dated by the parent/legal guardian and the written assent form must be signed and dated by the patient (if applicable). Note: Age requirements are as specified by local regulations.
  5. Outpatient >= 12 years of age on the date of consent/assent. In countries where the local regulations permit enrollment of adult patients only, patients must be 18 years of age and older.
  6. Asthma diagnosis: The patient has a diagnosis of asthma as defined by the National Institute of Health (NIH). The asthma diagnosis has been present for a minimum of 3 months and has been stable (defined as no exacerbations and no changes in asthma medication) for at least 30 days.
  7. The patient is able to perform acceptable and repeatable spirometry.
  8. The patient is able to perform peak expiratory flow (PEF) with a handheld peak flow meter.
  9. The patient is able to use a metered dose inhaler (MDI) device without a spacer device and a multidose dry powder inhaler (MDPI) device.
  10. The patient is able to withhold (as judged by the investigator) his or her regimen of ICS or study drug, and rescue medication for at least 6 hours before the screening visit (SV) and before all treatment visits.
  11. The patient/parent/legal guardian/caregiver is capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements.
  12. SABAs: All patients must be able to replace their current SABA with albuterol/salbutamol HFA MDI inhalation aerosol for the duration of the study.
  13. Female patients may not be pregnant, breastfeeding, or attempting to become pregnant.

    • other criteria may apply, please contact the investigator for more information

Exclusion Criteria:

  1. A history of a life-threatening asthma exacerbation (an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures).
  2. The patient is pregnant or lactating, or plans to become pregnant during the study period or for 30 days after the study.
  3. The patient has participated as a randomized patient in any investigational drug study within 30 days of the SV.
  4. The patient has previously participated as a randomized patient in a study of Fp MDPI or FS MDPI.
  5. The patient has a known hypersensitivity to any corticosteroid, salmeterol, or any of the excipients in the study drug or rescue medication formulation (ie, lactose).
  6. The patient has been treated with any known strong cytochrome P450 (CYP) 3A4 inhibitors (eg, azole antifungals, ritonavir, or clarithromycin) within 30 days before the SV.
  7. The patient has been treated with any of the prohibited medications during the prescribed (per protocol) washout periods before the SV.
  8. The patient currently smokes or has a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient must not have used tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco).
  9. The patient has a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that has not resolved at least 2 weeks before the SV.
  10. The patient has a history of alcohol or drug abuse within 2 years preceding the SV.
  11. The patient has had an asthma exacerbation requiring systemic corticosteroids within 30 days before the SV, or has had any hospitalization for asthma within 2 months before the SV.
  12. Initiation or dose escalation of immunotherapy (administered by any route) is planned during the study period. However, patients on stable immunotherapy may be considered for inclusion.
  13. The patient has used immunosuppressive medications within 4 weeks before the SV.
  14. The patient is unable to tolerate or unwilling to comply with the appropriate washout periods and withholding of all applicable medications.
  15. The patient has untreated oral candidiasis at the SV. Patients with clinical visual evidence of oral candidiasis who agree to receive treatment and comply with appropriate medical monitoring may enter the study.
  16. The patient has a history of a positive test for human immunodeficiency virus (HIV), active hepatitis B virus, or hepatitis C infection.
  17. The patient is either an employee or an immediate relative of an employee of the clinical investigational center.
  18. A member of the patient's household is participating in the study at the same time. However, after the enrolled patient completes or discontinues participation in the study, another patient from the same household may be screened.
  19. The patient has a disease/condition that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.

    • other criteria may apply, please contact the investigator for more information
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Czechia,   Hungary,   Poland,   Russian Federation,   South Africa,   Thailand,   Ukraine,   United States
Removed Location Countries Czech Republic,   Germany
 
Administrative Information
NCT Number  ICMJE NCT02141854
Other Study ID Numbers  ICMJE FSS-AS-30017
2014-000923-25 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
Study Sponsor  ICMJE Teva Branded Pharmaceutical Products, R&D Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Teva Medical Expert, MD Teva Pharmaceuticals USA
PRS Account Teva Pharmaceutical Industries
Verification Date May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP